Keynote  Address:

Lung Cancer 2012 — Where We Are and Where We’re Heading (Dr Jänne)

Genomics and Related Targeted Treatment of NSCLC:

EGFR mutations and acquired resistance to EGFR TKIs (Dr Lynch)

First-line therapy for metastatic EGFR mutation-positive NSCLC (Dr Heymach)

Novel strategies for targeting the EGFR pathway (Dr Jänne)

EML4-ALK translocations and crizotinib (Dr Wakelee)

Targeting MET in NSCLC (Dr Heymach)

Faculty Case Discussion 1

Comprehensive Management
of Metastatic NSCLC:

Chemobiologic treatment of advanced adenocarcinoma (Dr Wakelee)

Maintenance in metastatic adenocarcinoma of the lung (Dr Belani)

Anti-EGFR antibodies in NSCLC (Dr Lynch)

Systemic therapy for older patients (Dr Lilenbaum)

Chemobiologic treatment of advanced squamous cell carcinoma (Dr Socinski)

Faculty Case Discussion 2

Current Controversies in the Multidisciplinary Management of Lung Cancer:

Adjuvant systemic treatment of NSCLC (Dr Lilenbaum)

Stage III disease; PET/CT in radiation planning (Dr Curran)

Molecular prognostic biomarkers in early-stage lung cancer (Dr Jablons)

Developments in the treatment of SCLC (Dr Sandler)

Stereotactic radiosurgery (Dr Curran)

Faculty Case Discussion 4